254 related articles for article (PubMed ID: 32103422)
21. CT Radiogenomic Characterization of the Alternative Lengthening of Telomeres Phenotype in Pancreatic Neuroendocrine Tumors.
McGovern JM; Singhi AD; Borhani AA; Furlan A; McGrath KM; Zeh HJ; Bahary N; Dasyam AK
AJR Am J Roentgenol; 2018 Nov; 211(5):1020-1025. PubMed ID: 30160983
[TBL] [Abstract][Full Text] [Related]
22. Insights into Epigenetic Changes Related to Genetic Variants and Cells-of-Origin of Pancreatic Neuroendocrine Tumors: An Algorithm for Practical Workup.
Ciobanu OA; Martin SC; Herlea V; Fica S
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139607
[TBL] [Abstract][Full Text] [Related]
23. Alternative lengthening of telomeres predicts site of origin in neuroendocrine tumor liver metastases.
Dogeas E; Karagkounis G; Heaphy CM; Hirose K; Pawlik TM; Wolfgang CL; Meeker A; Hruban RH; Cameron JL; Choti MA
J Am Coll Surg; 2014 Apr; 218(4):628-35. PubMed ID: 24655849
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathological characteristics and non-adhesive organ culture of insulinomas.
Hoem D; Jensen D; Steine S; Thorsen TE; Viste A; Molven A
Scand J Surg; 2008; 97(1):42-9. PubMed ID: 18450205
[TBL] [Abstract][Full Text] [Related]
25. Intra-arterial calcium stimulation test for detection of insulinomas: detection rate, responses of pancreatic peptides, and its relationship to differentiation of tumor cells.
Won JG; Tseng HS; Yang AH; Tang KT; Jap TS; Kwok CF; Lee CH; Lin HD
Metabolism; 2003 Oct; 52(10):1320-9. PubMed ID: 14564685
[TBL] [Abstract][Full Text] [Related]
26. Leiomyosarcoma with alternative lengthening of telomeres is associated with aggressive histologic features, loss of ATRX expression, and poor clinical outcome.
Liau JY; Tsai JH; Jeng YM; Lee JC; Hsu HH; Yang CY
Am J Surg Pathol; 2015 Feb; 39(2):236-44. PubMed ID: 25229770
[TBL] [Abstract][Full Text] [Related]
27. Increased EpCAM expression in malignant insulinoma: potential clinical implications.
Raffel A; Eisenberger CF; Cupisti K; Schott M; Baldus SE; Hoffmann I; Aydin F; Knoefel WT; Stoecklein NH
Eur J Endocrinol; 2010 Feb; 162(2):391-8. PubMed ID: 20097833
[TBL] [Abstract][Full Text] [Related]
28. Alternative Lengthening of Telomeres Phenotype Predicts Progression Risk in Noninsulinomas in a Chinese Cohort.
Ban X; Mo S; Lu Z; Jia C; Shao H; Yan J; Chang X; Mao X; Wu Y; Zhang Y; Fan X; Yu S; Chen J
Neuroendocrinology; 2022; 112(5):510-522. PubMed ID: 34348341
[TBL] [Abstract][Full Text] [Related]
29. Novel prognostic markers revealed by a proteomic approach separating benign from malignant insulinomas.
Alkatout I; Friemel J; Sitek B; Anlauf M; Eisenach PA; Stühler K; Scarpa A; Perren A; Meyer HE; Knoefel WT; Klöppel G; Sipos B
Mod Pathol; 2015 Jan; 28(1):69-79. PubMed ID: 24947143
[TBL] [Abstract][Full Text] [Related]
30. ATRX loss is an independent predictor of poor survival in pancreatic neuroendocrine tumors.
Chou A; Itchins M; de Reuver PR; Arena J; Clarkson A; Sheen A; Sioson L; Cheung V; Perren A; Nahm C; Mittal A; Samra JS; Pajic M; Gill AJ
Hum Pathol; 2018 Dec; 82():249-257. PubMed ID: 30081149
[TBL] [Abstract][Full Text] [Related]
31. Molecular parameters associated with insulinoma progression: chromosomal instability versus p53 and CK19 status.
Jonkers YM; Claessen SM; Veltman JA; Geurts van Kessel A; Dinjens WN; Skogseid B; Ramaekers FC; Speel EJ
Cytogenet Genome Res; 2006; 115(3-4):289-97. PubMed ID: 17124412
[TBL] [Abstract][Full Text] [Related]
32. Frequency and clinical correlates of somatic Ying Yang 1 mutations in sporadic insulinomas.
Lichtenauer UD; Di Dalmazi G; Slater EP; Wieland T; Kuebart A; Schmittfull A; Schwarzmayr T; Diener S; Wiese D; Thasler WE; Reincke M; Meitinger T; Schott M; Fassnacht M; Bartsch DK; Strom TM; Beuschlein F
J Clin Endocrinol Metab; 2015 May; 100(5):E776-82. PubMed ID: 25763608
[TBL] [Abstract][Full Text] [Related]
33. Prognostic and Predictive Biomarkers for Pancreatic Neuroendocrine Tumors.
Hackeng WM; Assi HA; Westerbeke FHM; Brosens LAA; Heaphy CM
Surg Pathol Clin; 2022 Sep; 15(3):541-554. PubMed ID: 36049835
[TBL] [Abstract][Full Text] [Related]
34. Alternative Lengthening of Telomeres (ALT) in Pancreatic Neuroendocrine Tumors: Ready for Prime-Time in Clinical Practice?
Luchini C; Lawlor RT; Bersani S; Vicentini C; Paolino G; Mattiolo P; Pea A; Cingarlini S; Milella M; Scarpa A
Curr Oncol Rep; 2021 Jul; 23(9):106. PubMed ID: 34269919
[TBL] [Abstract][Full Text] [Related]
35. Comparison of benign and malignant insulinoma.
Sada A; Yamashita TS; Glasgow AE; Habermann EB; Thompson GB; Lyden ML; Dy BM; Halfdanarson TR; Vella A; McKenzie TJ
Am J Surg; 2021 Feb; 221(2):437-447. PubMed ID: 32873371
[TBL] [Abstract][Full Text] [Related]
36. Surgical management of insulinomas: short- and long-term outcomes after enucleations and pancreatic resections.
Crippa S; Zerbi A; Boninsegna L; Capitanio V; Partelli S; Balzano G; Pederzoli P; Di Carlo V; Falconi M
Arch Surg; 2012 Mar; 147(3):261-6. PubMed ID: 22430908
[TBL] [Abstract][Full Text] [Related]
37. Metastatic insulinoma: current molecular and cytotoxic therapeutic approaches for metastatic well-differentiated panNETs.
Giuroiu I; Reidy-Lagunes D
J Natl Compr Canc Netw; 2015 Feb; 13(2):139-44. PubMed ID: 25691605
[TBL] [Abstract][Full Text] [Related]
38. Giant insulinoma: a report of 3 cases and review of the literature.
Callacondo D; Arenas JL; Ganoza AJ; Rojas-Camayo J; Quesada-Olarte J; Robledo H
Pancreas; 2013 Nov; 42(8):1323-32. PubMed ID: 24152958
[TBL] [Abstract][Full Text] [Related]
39. Alternative lengthening of telomeres phenotype in malignant vascular tumors is highly associated with loss of ATRX expression and is frequently observed in hepatic angiosarcomas.
Liau JY; Tsai JH; Yang CY; Lee JC; Liang CW; Hsu HH; Jeng YM
Hum Pathol; 2015 Sep; 46(9):1360-6. PubMed ID: 26190196
[TBL] [Abstract][Full Text] [Related]
40. Giant pancreatic tumor with clinical characteristics of insulinoma but without common pathologic features.
Oberheim NA; Kim A; Farkas RL; Ruan DT; Schoeniger LO; Schiffhauer LM; Moalem J
Endocr Pract; 2011; 17(2):e12-6. PubMed ID: 21324828
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
